Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore Holdings plc reported updated Phase 1/2 data for brenetafusp monotherapy in heavily pretreated HLA-A*02:01-positive advanced melanoma patients, achieving a 6-month overall survival rate of 87% and disease control rate of 52%. The data support selecting a 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced mela…